Vaccines aid in saving lives from infectious diseases and biological warfare attacks. They should be safe and effective in all recipients;otherwise, the likelihood that those who are hyporesponsive to vaccines will transmit disease to vulnerable individuals and disrupt herd immunity is greatly increased. There is compelling evidence that smokers, who represent more than one billion people worldwide, are less responsive to vaccines (1-3). However, there currently is no scientific organization and commercial entity offering an enhanced vaccine or working on such optimization. We made progress in our understanding of the mechanisms that underlie the impairment of vaccine-induced immunity and reported that prophylactic and therapeutic vaccines fail to protect and cure animals from disease due to nicotine-induced defects in the biological activities of dendritic cells (DCs) (4). We also reported that the defects observed in DCs are reversible and IFN-g known to be produced by natural killer (NK) cells, is an absolute requirement in this process (5). Hence, we hypothesize that an adjustment of vaccine formulation with immunological adjuvant(s) capable of restoring interactions between DC and NK cells will allow vaccines to also work optimally in this population. Of note, our new preliminary data revealed that among TLR agonists tested, nicotine has limited adverse effect on DC and NK cells responses to a TLR7/8 agonist (Fig. 2). Importantly, addition of this agonist to the vaccine formulation significantly improves antigen-specific effector memory Th1 response in nicotine-exposed mice (Fig. 3C). Based on these findings, we propose to identify the signature of adjuvant(s) that can overcome the degrading effects of nicotine on vaccination outcome. The following aim is designed to accomplish this objective.
Aim : Determine the mechanisms by which the TLR7/8 agonist in contrast to other TLR agonists restores the efficacy of vaccines in nicotine-exposed hosts. At the completion of this study, we will have revealed the unknown mechanisms underlying the differential effectiveness of TLR agonists in nicotine-exposed hosts. We envision that such findings could be applied to further development of current and future vaccines.

Public Health Relevance

Centers for Disease Control (CDC) identified smokers as a population with higher incidence and severity of infectious diseases and recommended booster vaccines for all smokers. The benefit of such a recommendation, however, may be limited due to well-documented nicotine-induced systemic dampening of the immune function. The ultimate goal of this project is to protect the public health from contagious disease by optimizing the efficacy of current and future vaccines in smokers through the use of appropriate adjuvants. This is particularly important during epidemic season, pandemic outbreak, or biological warfare as 20% of the US population and 31% of military personnel are tobacco users.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Research Grants (R03)
Project #
5R03AI103750-02
Application #
8660622
Study Section
Immunity and Host Defense Study Section (IHD)
Program Officer
Palker, Thomas J
Project Start
2013-06-01
Project End
2015-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
2
Fiscal Year
2014
Total Cost
$74,708
Indirect Cost
$24,708
Name
Florida Atlantic University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
004147534
City
Boca Raton
State
FL
Country
United States
Zip Code
33431